Klein Hersh Recruits CFO for Sparrow Pharmaceuticals

September 21, 2026 – Klein Hersh, a search firm focused on the life sciences and healthcare industries, has recruited George Eldridge as the new CFO of Sparrow Pharmaceuticals, a targeted cardiometabolic therapeutics company. “We are thrilled to welcome George to Sparrow at such an important time for our company,” said Robert Jacks, president and CEO of Sparrow Pharmaceuticals. “George brings a rare combination of financial rigor and hands-on public company experience, having guided multiple biotechnology companies through IPOs and important, value-creating milestones. As we advance clofutriben for patients with difficult-to-control cardiometabolic disease, George’s leadership will be instrumental in positioning Sparrow for our next phase of growth.”

Mr. Eldridge brings more than two decades of biotechnology financial leadership, including experience guiding multiple companies through successful initial public offerings.

Most recently, he served as CFO of Abcuro, Inc., where he prepared the company for an initial public offering in anticipation of positive Phase 2/3 results in February 2026. Prior to Abcuro, Mr. Eldridge served for four years as CFO of Aerovate Therapeutics, Inc., which he took public in 2021. Earlier in his career, he served as senior vice president and CFO of Lyndra Therapeutics, Inc. and as a consultant and acting CFO to Sollis Therapeutics Inc. From 2013 to 2020, he was senior vice president and CFO of Proteon, where he led the company’s initial public offering. He also served as CFO of Targanta Therapeutics Corporation, which he took public prior to its acquisition by The Medicines Company in 2009, and previously held CFO roles at Curis, Inc. (formerly Ontogeny, Inc.) and Boston Life Sciences, Inc., both of which he also took public. Mr. Eldridge began his career as an investment banker at Kidder Peabody & Co, Inc.

“I am excited to join Sparrow at an important moment in the company’s evolution,” said Mr. Eldridge. “Elevated cortisol is an underappreciated but common upstream driver of poor outcomes across a broad population of patients who struggle to control their cardiometabolic disease, and clofutriben’s differentiated mechanism has the potential to address a significant unmet need. I look forward to partnering with Robert and the team to build the financial foundation to support Sparrow’s next stage of growth.”

Sparrow Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing targeted therapies for cardiometabolic diseases. The company’s lead drug candidate, clofutriben, is an oral HSD-1 inhibitor being evaluated for the treatment of difficult-to-control type 2 diabetes and related metabolic conditions associated with elevated cortisol.

Established in 1998, Klein Hersh is an executive search firm that partners with clients to deliver executive leaders for global pharmaceutical, biotech, and healthcare companies as well as operating businesses of PE and VC-backed investments. Noteworthy clients include Akero, Aktis Oncology, Apogee Therapeutics, ArchWell Health, Atlas Venture, Bain Capital Life Sciences, Biogen, Capital Rx, ConcertAI, CytoReason, Dispatch, Fairmount, Forbion, Foresite Capital, Frazier Healthcare Partners, Iambic, ITM, Koa Health, LifeMine, LongueVue Capital, Lyric, MacroHealth, McKesson, Moderna, Morningside, Odyssey Therapeutics, Oruka Therapeutics, Pacira Biosciences, Inc., Paragon Therapeutics, Posterity Health, Revolution Medicines, TPG, Transformation Capital, Treeline Biosciences, and Unlearn.

Corrixr Therapeutics Search

Klein Hersh also recently placed Hilary M. Malone as the new CEO of Corrixr Therapeutics in Newark, DE. She succeeds Eric B. Kmiec, founder of Corrixr, who will continue to serve in his capacity as chief scientific officer and will remain actively engaged in the company’s scientific direction.

The Select Guide to America’s Top 250 Executive Search Firms

Hunt Scanlon Media proudly presents the Select Guide to America’s Top 250 Executive Search Firms.

This comprehensive online directory is your definitive resource for finding the best executive search firms to serve your talent needs.

Our guide is meticulously curated to connect you with leading firms that specialize in various industries and functions, ensuring you find the perfect match for your executive recruitment needs.

“Hilary’s appointment marks a critical step in our shared mission to bring a fundamentally new approach to patients with squamous cell cancers,” said Janice E. Nevin, chair of the Corrixr board and president and CEO of ChristianaCare. “Corrixr has built a compelling body of scientific evidence, and we believe Hilary has precisely the experience and vision to translate that science into the clinic and beyond. ChristianaCare is proud to be Corrixr’s founding institutional investor and partner, and we look forward to supporting the next chapter of this work.”

Dr. Malone brings more than 25 years of executive leadership experience across both multinational pharmaceutical companies and venture-backed biotech startups, combining deep expertise in science, regulatory strategy, clinical development, and patient/market access across the full drug development lifecycle. She is joining Corrixr at a pivotal moment as the company advances its lead program, CXR101, toward IND filing and first-in-human proof-of-mechanism trials.

Contributed by Scott A. Scanlon, Editor-in-Chief and Dale M. Zupsansky, Executive Editor – Hunt Scanlon Media

Share This Article

0 Comments

RECOMMENDED ARTICLES